Related Factors of Ischemia-Reperfusion Injury After Percutaneous Coronary Intervention in Acute Myocardial Infarction Caused by Hyperlipidemia Metabolic Diseases

Zice Su¹, Hongzhe Zhang², Yanqing Gong¹, Hao Liu², Xiaona Wu², Mingchuan Ba², Lijun Li², Yuqing Sui², Lin Guo², Fusheng Cai², Peiyuan Xu², Zhen Gao², Xiaomei Lan², Wen Ou², Xiaomin Li^2,*

¹The Second Clinical Medical School, Southern Medical University, Guangzhou 510515, Guangdong, China.

²Department of Cardiology, The Seventh Affiliated Hospital of Southern Medical University, Foshan 528200, Guangdong, China.

*Corresponding author: Xiaomin Li

Published: February 26,2025

Abstract

Objective: To explore the relevant analysis of ischemia-perfusion injury (IRI) after receiving primary percutaneous coronary intervention (PPCI) in patients with acute myocardial infarction (AMI). Methods: A retrospective analysis was conducted on 106 AMI patients hospitalized and undergoing emergency coronary intervention in the Department of Cardiovascular Medicine at the Seventh Affiliated Hospital of Southern Medical University and the Third Affiliated Hospital of Guizhou Medical University from March to December 2021. Data collected included demographics, risk factors, and medication history. Blood tests measured lipid profiles (lipoprotein [LPa], HDL-C, LDL-C, ApoA1, Apo-B), leukocyte and platelet counts, and troponin levels. Patients were categorized by ischemia-reperfusion injury (IRI) status post-PCI, and the correlation between IRI and preoperative lipid levels, and troponin was assessed. Univariate and multivariate logistic regression identified IRI risk factors after PCI in AMI patients. A nomogram-based risk prediction model for post-PCI IRI in AMI was developed and validated using ROC curves for discriminative power. Results: One-way regression analysis showed that diabetes (OR: 5.21; 95% CI: 0.15-0.88; P<0.05), LDL-C (OR: 3.31; 95% CI: 1.50-7.30; P<0.01), APO-B (OR: 2.83; 95% CI: 1.29-6.20; P<0.01) and TnI (OR: 4.29; 95% CI: 1.90-9.69; P<0.01) were correlated with the occurrence of IRI after surgery. Multifactorial regression analysis showed that diabetes (OR: 7.26; 95% CI: 1.45-10.59; P<0.01), APO-B (OR: 7.62; 95% CI: 0.1-0.68; P<0.01), TnI (OR: 13.74; 95% CI. 0.05-0.39; P<0.01) were independent risk factors for ischaemia-reperfusion injury after PCI. Preoperative TnI had the best discriminatory ability to predict the occurrence of IRI after PCI with an AUC of 0.68 (95% CI: 0.58-0.78), a sensitivity of 63.5%, a specificity of 72.2% and cut-off value of 2.83. Conclusions: Preoperative diabetes, APO-B, and TnI are independent risk factors for the development of ischaemia-reperfusion injury after PCI. Of these, preoperative TnI was the best predictor of the occurrence of IRI after PCI.

References

[1] De Roeck L, Vandamme S, Everaert BR, Hoymans V, Haine S, Vandendriessche T, et al. Adiponectin and ischemia-reperfusion injury in ST segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2016 Feb;5(1):71-6.

[2] Evaluating the role of intravenous pentoxifylline administration on primary percutaneous coronary intervention success rate in patients with ST-elevation myocardial infarction (PENTOS-PCI) - PubMed [Internet]. [cited 2024 Nov 21]. Available from:
https://pubmed.ncbi.nlm.nih.gov/36856810/.

[3] Colchicine to Prevent Sympathetic Denervation after an Acute Myocardial Infarction: The COLD-MI Trial Protocol - PubMed [Internet]. [cited 2024 Nov 21]. Available from:
https://pubmed.ncbi.nlm.nih.gov/34684084/.

[4] Majidi M, Kosinski AS, Al-Khatib SM, Smolders L, Cristea E, Lansky AJ, et al. Implications of ventricular arrhythmia “bursts” with normal epicardial flow, myocardial blush, and ST-segment recovery in anterior ST-elevation myocardial infarction reperfusion: a biosignature of direct myocellular injury “downstream of downstream.” Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):51-9.

[5] Majidi M, Kosinski AS, Al-Khatib SM, Lemmert ME, Smolders L, van Weert A, et al. Reperfusion ventricular arrhythmia “bursts” predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction. Eur Heart J. 2009 Apr;30(7):757-64.

[6] Chen W, Zhang Y, Wang Z, Tan M, Lin J, Qian X, et al. Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition. Front Pharmacol. 2023;14:1078205.

[7] Verma S, Fedak PWM, Weisel RD, Butany J, Rao V, Maitland A, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002 May 21;105(20):2332-6.

[8] Gunata M, Parlakpinar H. A review of myocardial ischaemia/reperfusion injury: Pathophysiology, experimental models, biomarkers, genetics and pharmacological treatment. Cell Biochem Funct. 2021 Mar;39(2):190-217.

[9] Maxwell SR, Lip GY. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int J Cardiol. 1997 Jan 31;58(2):95-117.

[10] Rentrop KP, Feit F. Reperfusion therapy for acute myocardial infarction: Concepts and controversies from inception to acceptance. Am Heart J. 2015 Nov;170(5):971-80.

[11] Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-639.

[12] Correction to: Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Sep 6;146(10):e141.

[13] Robinson KA, Akbar N, Baidžajevas K, Choudhury RP. Trained immunity in diabetes and hyperlipidemia: Emerging opportunities to target cardiovascular complications and design new therapies. FASEB J Off Publ Fed Am Soc Exp Biol. 2023 Nov;37(11):e23231.

[14] Tian H, Xiong Y, Zhang Y, Leng Y, Tao J, Li L, et al. Activation of NRF2/FPN1 pathway attenuates myocardial ischemia-reperfusion injury in diabetic rats by regulating iron homeostasis and ferroptosis. Cell Stress Chaperones. 2021 Mar;27(2):149-64.

[15] Li W, Li W, Wang Y, Leng Y, Xia Z. Inhibition of DNMT-1 alleviates ferroptosis through NCOA4 mediated ferritinophagy during diabetes myocardial ischemia/reperfusion injury. Cell Death Discov. 2021 Sep 29;7(1):267.

[16] Tian H, Xiong Y, Zhang Y, Leng Y, Tao J, Li L, et al. Activation of NRF2/FPN1 pathway attenuates myocardial ischemia-reperfusion injury in diabetic rats by regulating iron homeostasis and ferroptosis. Cell Stress Chaperones. 2021 Mar;27(2):149-64.

[17] Li JY, Liu SQ, Yao RQ, Tian YP, Yao YM. A Novel Insight Into the Fate of Cardiomyocytes in Ischemia-Reperfusion Injury: From Iron Metabolism to Ferroptosis. Front Cell Dev Biol. 2021;9:799499.

[18] Aggarwal DJ, Kathariya MG, Verma DPK. LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker. Indian Heart J. 2021;73(5):544-8.

[19] Rosenblit PD. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk. Curr Diab Rep. 2019 Nov 21;19(12):146.

[20] Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem. 2002 Feb;48(2):236-54.

[21] Rifai N, Warnick GR, McNamara JR, Belcher JD, Grinstead GF, Frantz ID. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem. 1992 Jan;38(1):150-60.

[22] Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev. 2022 Jul 13;43(4):611-53.

[23] Su X, Wang M, Zuo Y, Wen J, Zhai Q, Zhang Y, et al. Apolipoprotein Particle and Cardiovascular Risk Prediction (from a Prospective Cohort Study). Am J Cardiol. 2023 Aug 15;201:34-41.

[24] Ramjee V, Sperling LS, Jacobson TA. Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math. J Am Coll Cardiol. 2011 Jul 26;58(5):457-63.

[25] Sattar N, Williams K, Sniderman AD, D’Agostino R, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004 Oct 26;110(17):2687-93.

[26] Su X, Cai X, Pan Y, Sun J, Jing J, Wang M, et al. Discordance of apolipoprotein B with low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol and coronary atherosclerosis. Eur J Prev Cardiol. 2022 Dec 21;29(18):2349-58.

[27] Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation. 2004 Nov 2;110(18):2824-30.

[28] Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45.

[29] Sweetnam PM, Bolton CH, Downs LG, Durrington PN, MacKness MI, Elwood PC, et al. Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study. Eur J Clin Invest. 2000 Nov;30(11):947-56.

[30] Sabino AP, De Oliveira Sousa M, Moreira Lima L, Dias Ribeiro D, Sant’Ana Dusse LM, Das Graças Carvalho M, et al. ApoB/ApoA-I ratio in young patients with ischemic cerebral stroke or peripheral arterial disease. Transl Res J Lab Clin Med. 2008 Sep;152(3):113-8.

[31] Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005 Nov 29;112(22):3375-83.

[32] Kazumi T, Kawaguchi A, Hirano T, Yoshino G. Serum adiponectin is associated with high-density lipoprotein cholesterol, triglycerides, and low-density lipoprotein particle size in young healthy men. Metabolism. 2004 May;53(5):589-93.

[33] Brulhart-Meynet MC, Braunersreuther V, Brinck J, Montecucco F, Prost JC, Thomas A, et al. Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury. PloS One. 2015;10(3):e0119664.

[34] Suematsu Y, Miura S ichiro, Takata K, Shimizu T, Kuwano T, Imaizumi S, et al. A novel inducible cholesterol efflux peptide, FAMP, protects against myocardial ischemia reperfusion injury through a nitric oxide pathway. Int J Cardiol. 2016 Jan 1;202:810-6.

[35] Volz HC, Buss SJ, Li J, Göser S, Andrassy M, Ottl R, et al. Autoimmunity against cardiac troponin I in ischaemia reperfusion injury. Eur J Heart Fail. 2011 Oct;13(10):1052-9.

[36] Gorjipour F, Saeedzadeh T, Toloueitabar Y, Kachoueian N, Bahlouli Ghashghaei S, Mortazian M, et al. Remote ischemic preconditioning effects on inflammatory markers and myocardial protection in coronary artery bypass graft surgery. Perfusion. 2022 Jan;37(1):56-61.

[37] Ye XD, He Y, Wang S, Wong GT, Irwin MG, Xia Z. Heart-type fatty acid binding protein (H-FABP) as a biomarker for acute myocardial injury and long-term post-ischemic prognosis. Acta Pharmacol Sin. 2018 Jul;39(7):1155-63.

[38] Olejnik A, Krzywonos-Zawadzka A, Banaszkiewicz M, Bil-Lula I. Klotho Protein Decreases MMP-Mediated Degradation of Contractile Proteins during Ischaemia/Reperfusion Injury to the Cardiomyocytes. Int J Mol Sci. 2022 Dec 7;23(24):15450.

[39] Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018 Nov 13;138(20):e618-51.

[40] Badings EA, Remkes WS, The SHK, Dambrink JHE, Tjeerdsma G, Rasoul S, et al. Early or late intervention in patients with transient ST-segment elevation acute coronary syndrome: Subgroup analysis of the ELISA-3 trial. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2016 Nov;88(5):755-64.

[41] Karwowski J, Poloński L, Gierlotka M, Ciszewski A, Hawranek M, Bęćkowski M, et al. Total coronary occlusion of infarct-related arteries in patients with non-ST-elevation myocardial infarction undergoing percutaneous coronary revascularisation. Kar-diol Pol. 2017;75(2):108-16.

How to cite this paper

Related Factors of Ischemia-Reperfusion Injury After Percutaneous Coronary Intervention in Acute Myocardial Infarction Caused by Hyperlipidemia Metabolic Diseases

How to cite this paper: Zice Su, Hongzhe Zhang, Yanqing Gong, Hao Liu, Xiaona Wu, Mingchuan Ba, Lijun Li, Yuqing Sui, Lin Guo, Fusheng Cai, Peiyuan Xu, Zhen Gao, Xiaomei Lan, Wen Ou, Xiaomin Li. (2025) Related Factors of Ischemia-Reperfusion Injury After Percutaneous Coronary Intervention in Acute Myocardial Infarction Caused by Hyperlipidemia Metabolic Diseases. International Journal of Clinical and Experimental Medicine Research, 9(1), 82-94.

DOI: http://dx.doi.org/10.26855/ijcemr.2025.01.015

International Journal of Clinical and Experimental Medicine Research

Journal Menu

Volumes & Issues

Current Issue

More Articles

Related Factors of Ischemia-Reperfusion Injury After Percutaneous Coronary Intervention in Acute Myocardial Infarction Caused by Hyperlipidemia Metabolic Diseases

Abstract

References

How to cite this paper